October 29, 2013
Tulane University School of Medicine is looking for volunteers to take part in the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay Type 2 diabetes in adults with prediabetes.
Tulane is one of 20 sites across the country to take part in the National Institutes of Health-funded study, which is recruiting about 2,500 participants, said local study leader Dr. Vivian Fonseca, Tullis-Tulane Alumni Chair in Diabetes.
The Vitamin D and Type 2 Diabetes (D2d) study will investigate whether vitamin D – specifically D3 (cholecalciferol) – will prevent or delay Type 2 diabetes in adults aged 30 or older with prediabetes. People with prediabetes have blood glucose levels that are higher than normal but not high enough to be called diabetes.
D2d is the first study to directly examine if a daily dose of 4,000 International Units of vitamin D helps prevent the onset of Type 2 Ddiabetes. Researchers speculate that vitamin D could reduce the diabetes risk by 25 percent. The study will also examine if gender, age or race affect the potential of vitamin D to reduce diabetes risk.
The study will be double-blinded and participants will receive either vitamin D or a placebo. The study will continue until enough people have developed Type 2 diabetes to be able to make a scientifically valid comparison between diabetes development in the two groups, likely about four years.
To learn more about participating in the study, call 504-988-0200 or visit www.D2dstudy.org.
D2d (ClinicalTrials.gov number NCT01942694) is supported under NIH grant U01DK098245. The National Institute of Diabetes and Digestive and Kidney Diseases is the primary sponsor of the trial, with additional support from the NIH Office of Dietary Supplements and the American Diabetes Association. Support in the form of educational materials is provided by the National Diabetes Education Program.
Tulane University, New Orleans, LA 70118 504-865-5000 email@example.com